One of the primary treatments for toxoplasmosis involves the use of pyrimethamine (PM) (Figure 1), an antiparasitic drug that targets dihydrofolate reductase (DHFR) within the folate metabolism pathway [2]. Here, DHFR is linked to toxoplasmosis.